Teligent Free Cash Flow 2011-2021 | TLGT
Teligent free cash flow from 2011 to 2021. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Teligent Annual Free Cash Flow | |
|---|---|
| 2020 | -20.66 |
| 2019 | -26.62 |
| 2018 | -38.57 |
| 2017 | -40.03 |
| 2016 | -17.10 |
| 2015 | -21.51 |
| 2014 | -4.73 |
| 2013 | -0.91 |
| 2012 | -2.72 |
| 2011 | -2.74 |
| 2010 | -3.21 |
| Teligent Quarterly Free Cash Flow | |
|---|---|
| 2021-06-30 | -17.64 |
| 2021-03-31 | -10.92 |
| 2020-12-31 | -20.66 |
| 2020-09-30 | -18.77 |
| 2020-06-30 | -13.51 |
| 2020-03-31 | -3.83 |
| 2019-12-31 | -26.62 |
| 2019-09-30 | -14.74 |
| 2019-06-30 | -15.39 |
| 2019-03-31 | -8.18 |
| 2018-12-31 | -38.57 |
| 2018-09-30 | -33.59 |
| 2018-06-30 | -25.03 |
| 2018-03-31 | -13.64 |
| 2017-12-31 | -40.03 |
| 2017-09-30 | -28.66 |
| 2017-06-30 | -16.59 |
| 2017-03-31 | -6.67 |
| 2016-12-31 | -17.10 |
| 2016-09-30 | -9.14 |
| 2016-06-30 | -2.51 |
| 2016-03-31 | 0.20 |
| 2015-12-31 | -21.51 |
| 2015-09-30 | -2.41 |
| 2015-06-30 | -7.07 |
| 2015-03-31 | -0.33 |
| 2014-12-31 | -4.73 |
| 2014-09-30 | -1.65 |
| 2014-06-30 | -0.78 |
| 2014-03-31 | -0.01 |
| 2013-12-31 | -0.91 |
| 2013-09-30 | -1.61 |
| 2013-06-30 | -1.10 |
| 2013-03-31 | -1.65 |
| 2012-12-31 | -2.72 |
| 2012-09-30 | -1.52 |
| 2012-06-30 | -1.27 |
| 2012-03-31 | -0.73 |
| 2011-12-31 | -2.74 |
| 2011-09-30 | -2.69 |
| 2011-06-30 | -2.29 |
| 2011-03-31 | -0.98 |
| 2010-12-31 | -3.21 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $27.493B | 9.29 |
| BridgeBio Pharma (BBIO) | United States | $11.909B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.238B | 16.62 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.580B | 21.61 |
| Bausch Health Cos (BHC) | Canada | $2.466B | 1.75 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.117B | 7.96 |
| Taysha Gene Therapies (TSHA) | United States | $1.049B | 0.00 |
| Personalis (PSNL) | United States | $0.615B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.239B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.085B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.017B | 0.00 |